Teva Pharmaceutical Industries Limited (NYSE:TEVA)

TEVA Pharmaceuticals USA, the business is to develop, manufacture, and market generic pharmaceuticals.  Teva USA sells its products to chains, wholesalers, distributors, hospitals, managed care entities, and government agencies.  The company markets a variety of dosage forms, including both extended and immediate release tablets and capsules, creams, ointments, solutions, and suspensions.  Key therapeutic areas are the analgesic, anti-infective, cardiovascular, CNS, dermatological and anti-inflammatory categories.

Teva Pharmaceutical Industries Limited (NYSE:TEVA)’s Financial Overview

Teva Pharmaceutical Industries Limited (NYSE:TEVA) declined -0.76% yesterday to close its trading session at $37.86. The company has 1 year Price Target of $54.87. Teva Pharmaceutical Industries Limited has 52-Week high of $66.55 and 52-Week Low of $37.12. The stock touched its 52-Week High on Dec 30, 2015 and 52-Week Low on Nov 23, 2016. The stock traded with the volume of 5.52 Million shares yesterday. The firm shows the market capitalization of $38.21 Billion.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) reported its last quarterly earnings on Jun 16 where the firm reported its Actual EPS of $1.25/share against the analyst consensus estimate of $1.2/share. The difference between the actual and expected EPS is $0.05 a share with a surprise factor of 4.2%.

The firm is trading with SMA20 of -4.65 Percent, SMA50 of -12.74 Percent and SMA200 of -25.35 percent. Teva Pharmaceutical Industries Limited has P/S value of 1.88 while its P/B value stands at 1.18. Similarly, the company has Return on Assets of 2.4 percent, Return on Equity of 5.7 percent and Return on Investment of 5.7 Percent. The company shows Gross Margin and Operating Margin of 55.8 percent and 15.9 percent respectively.

Many brokerage firms are involved in issuing their ratings on Teva Pharmaceutical Industries Limited (NYSE:TEVA). On 16-Nov-16 Morgan Stanley Downgrade Teva Pharmaceutical Industries Limited Stock  to Equal-Weight. Another firm also rated the stock on 16-Nov-16 where Jefferies Downgrade the stock to Hold.

The Stock currently has Analyst’ mean Recommendation of 2 where the scale is from 1 to 5, 1 means Strong Buy and 5 means Sell.

The 25 analysts offering 12-month price forecasts for Teva Pharmaceutical have a median target of 50.00, with a high estimate of 100.00 and a low estimate of 40.00. The median estimate represents a +32.07% increase from the last price of 37.86.

Our vendor, Zacks Investment Research, hasn’t provided us with the upcoming earnings report date.

The Mosaic Company (NYSE:MOS)

The Mosaic Company is one of the world’s leading producers and marketers of concentrated phosphate and potash crop nutrients. For the global agriculture industry, Mosaic is a single source for phosphates, potash, nitrogen fertilizers and feed ingredients.

The Mosaic Company (NYSE:MOS)’s Financial Outlook

The 21 analysts offering 12-month price forecasts for Mosaic Co have a median target of 24.00, with a high estimate of 33.00 and a low estimate of 19.00. The median estimate represents a -11.31% decrease from the last price of 27.06.

Our vendor, Zacks Investment Research, hasn’t provided us with the upcoming earnings report date.

According to Zacks Investment Research, The Mosaic Company has a Consensus Recommendation of 3.2. (The Scale is from 1-5 where 1 means Strong Buy and 5 means Strong Sell).

The Stock fell -1.06% and closed its last trading session at $27.06. The company has the market capitalization of $9.48 Billion. The stock has 52-week high of $32.26 and 52-Week low of $22.02. The firm touched its 52-Week high on Dec 7, 2015 and 52-Week low on Feb 2, 2016. The company has volume of 5.49 Million shares. The company has a total of 350.24 Million shares outstanding.

The Mosaic Company (NYSE:MOS) in the last quarter reported its actual EPS of $0.41/share where the analyst estimated EPS was $0.1/share. The difference between the actual and Estimated EPS is $0.31. This shows a surprise factor of 310 percent.

The company has YTD performance of 1.12 percent. Beta for The Mosaic Company stands at 1.3 while its ATR (average true range) is 0.93. The company has Weekly Volatility of 3.57%% and Monthly Volatility of 3.64%%.

The Mosaic Company has distance from 20-day Simple Moving Average (SMA20) of 1.61%, Distance from 50-Day Simple Moving Average of 6.99 percent and Distance from 200-Day Simple Moving Average of 2.37%.

The Company currently has ROA (Return on Assets) of 2.5 percent, Return on Equity (ROE) of 4.5 Percent and Return on Investment (ROI) of 8.8% with Gross margin of 12.9 percent and Operating & Profit margin of 6% and 5.9% respectively.